MIRUM PHARMACEUTICALS, INC. (MIRM)
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
📈 **POSITIVE** • High confidence analysis (90%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business